Clinical Trial Update: Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing the safety of Avonex (interferon beta-1a) in multiple sclerosis patients who have neutralizing antibodies to interferon beta ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED